Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published December 27, 2012 | Accepted Version + Published + Supplemental Material
Journal Article Open

Epistasis between MicroRNAs 155 and 146a during T Cell-Mediated Antitumor Immunity

Abstract

An increased understanding of antitumor immunity is necessary for improving cell-based immunotherapies against human cancers. Here, we investigated the roles of two immune system-expressed microRNAs (miRNAs), miR-155 and miR-146a, in the regulation of antitumor immune responses. Our results indicate that miR-155 promotes and miR-146a inhibits interferon γ (IFNγ) responses by T cells and reduces solid tumor growth in vivo. Using a double-knockout (DKO) mouse strain deficient in both miR-155 and miR-146a, we have also identified an epistatic relationship between these two miRNAs. DKO mice had defective T cell responses and tumor growth phenotypes similar to miR-155^(−/−) mice. Further analysis of the T cell compartment revealed that miR-155 modulates IFNγ expression through a mechanism involving repression of Ship1. Our work reveals critical roles for miRNAs in the reciprocal regulation of CD4^+ and CD8^+ T cell-mediated antitumor immunity and demonstrates the dominant nature of miR-155 during its promotion of immune responses.

Additional Information

© 2012 The Authors. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-No Derivative Works License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited. Received: June 11, 2012; Revised: October 15, 2012; Accepted: October 30, 2012; Published: November 29, 2012. We would like to thank Allan Bradley for generously providing miR-155-/-mice, Lili Yang for providing the EL4-luc cells, and Glenn Dranoff for the B16-F10 cells. D.B. is a scientific advisor to Regulus Therapeutics, a company devoted to microRNA therapeutics. R.M.O. is supported by the National Institutes of Health grant 5R00HL102228-04.

Attached Files

Published - 1-s2.0-S2211124712003804-main.pdf

Accepted Version - nihms-419745.pdf

Supplemental Material - mmc1.pdf

Files

nihms-419745.pdf
Files (9.2 MB)
Name Size Download all
md5:7f3531381b7a8cdfa51b99ef710f8113
3.4 MB Preview Download
md5:d2aa87883576127153415974954086c2
2.6 MB Preview Download
md5:3d524df02bca9aa3d6085cb54101a44b
3.2 MB Preview Download

Additional details

Created:
August 19, 2023
Modified:
October 23, 2023